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Abstract Human mesenchymal stem cells (MSCs) are adult
multipotent progenitor cells. They hold an enormous thera-
peutic potential, but at the moment there is little information
on the properties of MSCs, including their surface structures.
In the present study, we analyzed the mesenchymal stem cell
glycome by using mass spectrometric profiling as well as a
panel of glycan binding proteins. Structural verifications were
obtained by nuclear magnetic resonance spectroscopy, mass
spectrometric fragmentation, and glycosidase digestions. The
MSC glycome was compared to the glycome of
corresponding osteogenically differentiated cells. More than
one hundred glycan signals were detected in mesenchymal
stem cells and osteoblasts differentiated from them. The
glycan profiles of MSCs and osteoblasts were consistently
different in biological replicates, indicating that stem cells
and osteoblasts have characteristic glycosylation features.
Glycosylation features associated with MSCs rather than
differentiated cells included high-mannose type N-glycans,
linear poly-N-acetyllactosamine chains and α2-3-sialylation.
Mesenchymal stem cells expressed SSEA-4 and sialyl Lewis
x epitopes. Characteristic glycosylation features that appeared
in differentiated osteoblasts included abundant sulfate ester
modifications. The results show that glycosylation analysis
can be used to evaluate MSC differentiation state.
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Introduction
Human stem cells possess an enormous potential for
future regenerative medicine. However, the clinical use of
human pluripotent embryonic stem cells has to overcome
numerous ethical and technical barriers. Therefore, the use
of adult multipotent stem cells is a noteworthy alternative
to fulfill the therapeutic expectations [1, 2].
Human mesenchymal stem cells (MSCs) or mesenchymal
stromal cells are fibroblast-like adult multipotent progenitor
cells that reside in several anatomical locations, for example
in bone marrow and in adipose tissue [3, 4]. The presence of
MSCs in blood has been demonstrated in rodents [5] with
their major function being the repair of injured tissues [4].
MSCs have also been reportedly isolated from human cord
blood [6, 7]. MSCs have been shown to have the potential
to differentiate at least into adipocytes, chondrocytes,
osteoblasts, myoblasts and tenocytes in vitro [4].
The therapeutic potential of MSCs is yet to be defined.
In vitro and in vivo experimental results are very promising
and suggest that MSC therapy can be applied in many
acute and subacute conditions to enhance or direct the
spontaneous healing process. There are preliminary results
of the successful use of MSCs to promote myocardial repair
after acute infarction [8] and bone repair [9]. Other
implications where MSC therapy has been successful
include osteogenesis imperfecta [10] and acute graft-
versus-host disease (GvHD) [11]. Preliminary clinical data
also exist on the treatment of spinal cord injury with MSCs
[12]. All this emerging evidence suggests that cellular
therapy is in the process of becoming part of the everyday
clinical practice, although the key applications remain to be
established.
In order to fulfill the expectations raised by MSCs for
stem cell therapy, several biological questions need to be
addressed. A specific molecular marker for MSCs to be
used in the preparation of pure stem cell populations does
not exist. Moreover, there is a need for a validated MSC
culture protocol in order to enhance the proliferation of
MSCs for either autologous or allogenic transplants, and to
produce MSCs free of animal-derived materials and of
sufficient purity for therapeutic purposes. Precise and
accurate information on the in vivo distribution of MSCs
upon transplantation needs to be established in order to
obtain the desired transplantation outcome. For all these
purposes any additional and novel information about MSC
surface structures would be beneficial.
Cell surface structures are generally known to be
involved in the interactions between cells as well as in the
binding of cells to the extracellular matrix. Of the 3 main
cell surface macromolecule classes, proteins as mere
polypeptides have previously been assumed to convey the
majority of plasma membrane functions, such as acting as
receptors, transporters and adhesive molecules. Lipids and
glycans have been considered less important for these
cellular functions throughout the history of biological
science. Only in the last few decades has the functional
status of the glycocalyx covering all cell surfaces been fully
appreciated, partly through technological developments in
glycoscience, and also through genetic and molecular
insights into glycoconjugate biosynthesis and recognition.
These glycans attached to either membrane proteins or
lipids have multiple and diverse roles in biology [13].
Glycobiology has been shown to play an important role
in mammalian development [14], starting from fertilization
of the oocyte. Further processes of development and
differentiation involve many specialized tasks carried out
by specific glycans and their receptors [13, 15]. A well-
studied function of polysialic acids in the development of
the nervous system can be mentioned as an example [16].
Transgenic animals deficient in glycosyltransferase genes
are often used as a model to study the effects of
glycosylation during developmental processes [17, 18].
The animal models used in these studies vary from
amphibians to mammals, with the mouse being the most
widely used model system. Cell surface glycans, however,
are known to be very species specific [19]. Therefore, direct
conclusions can not be drawn about the correspondence
between these animal studies and human developmental
processes.
Stem cell glycosylation has been shown to have unique
features, as presented in a recent review [20]. Recent
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reports discuss carbohydrate antigens mainly in embryonic
[21] and neural [16] stem cells. The majority of the studies
performed to date have been carried out by using different
glycan binding proteins, e.g. lectins or antibodies against
glycan epitopes [22–24]. Of these binders, antibodies
against SSEA-3, SSEA-4, Tra-1–60, Tra-1–81 [25, 26]
have been generally accepted as tools for embryonic stem
cell validation [27]. We have documented the glycan
structures in hematopoietic stem cells and further verified
glycosyltransferase gene expression profiles that are con-
sistent with observed glycan structures [28].
In this study, we have used mass spectrometric (MS)
profiling and nuclear magnetic resonance (NMR) spectros-
copy to study the cellular glycome of bone marrow-derived
MSCs and osteoblasts derived from them. We have
characterized specific glycan structures by specific glyco-
sidase enzymes, mass spectrometric fragmentation analyses
and high resolution MS. The cell surface presentation of
certain glycan epitopes has been further verified by staining
the cells with antibodies and lectins.
Materials and methods
Cells
Bone marrow-derived MSCs were obtained as described
previously [29]. In brief, bone marrow from femoral collum
and trochanteric region obtained during orthopedic surgery
was cultured in minimum essential α-medium (α-MEM),
supplemented with 20 mM HEPES, 10% fetal calf serum,
1× penicillin-streptomycin, and 2 mM L-glutamine (all
from Gibco). After a cell attachment period of 2 days, the
cells were washed with Ca2+ and Mg2+-free phosphate-
buffered saline (PBS) (Gibco) and subcultured further by
plating the cells at a density of 2,000 to 3,000 cells/cm2 in
the same medium. Half of the medium was replaced by
fresh medium twice a week until confluence was almost
reached.
The MSC lines used were analyzed for MSC phenotype as
described [30]. The cell lines were analyzed by flow
cytometry for the expression of the MSC markers (CD73,
CD90 and CD105) and the absence of differentiation markers
(CD14, CD19, CD34, CD45 and HLA-DR). Fluorescein
isothiocyanate (FITC)- or phycoerythrin-conjugated anti-
bodies against CD14, CD34, CD45 and CD73 were from
BD Biosciences (San Jose, CA) and against CD105 from
Abcam Ltd. (Cambridge, U.K.). FITC- and phycoerythrin-
conjugated isotypic controls were from BD Biosciences.
Unconjugated antibodies against CD90 and human leuko-
cyte antigens HLA-DR were from BD Biosciences.
FITC-conjugated goat anti-mouse IgG antibody was from
Sigma-Aldrich.
Five different MSC lines were used for mass spectro-
metric analyses and 3 of these were used in flow cytometry
and cytochemical stainings.
Osteogenic differentiation of mesenchymal stem cells
Induction of the osteogenic differentiation of the bone
marrow-derived MSCs was carried out essentially as
described [30]. The osteogenic induction medium consisted
of α-MEM (Gibco) supplemented with 10% fetal calf
serum (Gibco), 20 mM HEPES (Gibco), 0.1 μM dexa-
methasone (Decadron; Merck & Co., Inc., Whitehouse
Station, NJ), 10 mM ß-glycerophosphate, 0.05 mM L-
ascorbic acid-2-phosphate (Sigma-Aldrich), and penicillin-
streptomycin (Gibco). The cells were cultured for up to
6 weeks, changing the medium twice a week. Osteogenic
differentiation was evaluated by alkaline phosphatase
activity measurement and von Kossa staining [29].
Glycan binding proteins
Antibodies (Ab) against Lex (clone 28), sialyl Lex (sLex)
(KM93), SSEA-3 (MC-631) and SSEA-4 (MC-813-70)
were from Chemicon (Millipore; Billerica, MA). FITC-
labeled lectins, HHA from Hippeastrum hybrid, MAA from
Maackia amurensis, PWA from Phytolacca americana and
STA from Solanum tuberosum, were from EY Laboratories,
Inc. (San Mateo, CA, USA); SNA from Sambucus nigra
was from Vector Laboratories (Burlingame, CA, USA).
Glycan isolation
Cells were prepared for glycan analysis essentially as
described [28]. Cells were washed with PBS, scraped,
collected with PBS and centrifuged for 5 min at 400×g.
The pellet was washed twice with PBS and finally the cells
were collected by centrifugation. The cell pellet was stored at
−70°C and used for glycome analysis. Asparagine-linked
glycans were detached from cellular glycoproteins by F.
meningosepticum peptide:N-glycosidase F (PNGase F) di-
gestion (Calbiochem, San Diego). The released asparagine-
linked glycans (N-glycans) were purified for analysis by
organic extraction-precipitation and miniaturized solid-phase
extraction steps as described [28]. Serine- and threonine-
linked glycans (O-glycans) were detached from cellular
glycoproteins by non-reductive β-elimination with saturated
ammonium carbonate in concentrated ammonia at 60°C [31].
Glycosphingolipids were isolated by extraction using organic
solvents, phase partition (Folch’s phase), and gel filtration/
solid-phase extraction using a Sephadex G-25 (Amersham
Pharmacia) column [32]. Glycosphingolipid glycans were
detached by Macrobdella decora endoglycoceramidase
(Calbiochem) digestion. After isolation, both O-linked
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and sphingolipid-linked oligosaccharides were purified
similarly as N-glycans. Recoveries of N-glycans were
greater than either O-glycans or glycosphingolipid gly-
cans. For each N-glycan analysis, 300,000 to 500,000
cells were prepared. O-glycans were isolated from the
de-N-glycosylated protein samples recovered during the
precipitation-extraction purification step [28]. For subse-
quent O-glycan isolation, multiple glycoprotein samples
were pooled. For glycosphingolipid glycan isolation, 6 to
14 million cells were prepared. Aliquots of the glycan
fractions were used in each mass spectrometric analysis,
corresponding to on average 170,000 cells for N-glycans,
over 1 million cells for O-glycans, and on average 2.5
million cells for glycosphingolipid glycans. During glycan
purification with size-exclusion HPLC, we observed
absorbance peaks at 214 nm in the N-glycan area for both
neutral and acidic N-glycan fractions. Molar amounts of
recovered N-glycans were determined against external
GlcNAc and Neu5Ac standards at 214 nm using the most
abundant monosaccharide compositions in each fraction
for calculation: GlcNAc2 for neutral N-glycans and
Neu5Ac2GlcNAc4 for acidic N-glycans. The result of the
integration was 1 nmol total N-glycans/1 million MSCs.
Because the N-glycan fractions contained also larger
glycans with more GlcNAc or Neu5Ac residues as
determined by mass spectrometry, the result means that
actual recovery was less than 1 nmol/1 million cells.
Glycosidase treatments
Analysis of nonreducing glycan epitopes present in isolated
glycan fractions was performed by digestion with specific
glycosidase enzymes and subsequent mass spectrometric
detection as described [28]. Employed glycosidase enzymes
included β1,4-galactosidase (β4Gal; 0.9 mU/reaction, to
digest LacNAc but neither Galβ1-3GlcNAc nor Galα1-
3LacNAc) from Streptococcus pneumoniae (recombinant
in Escherichia coli; Calbiochem), β1,3-galactosidase
(β3Gal; 2.3 mU/reaction, to digest Galβ1-3GlcNAc) from
Xanthomonas manihotis (recombinant in E. coli; Calbio-
chem), α2,3-sialidase (α3SA; 3.5 mU/reaction, to digest
Neu5Acα2-3LacNAc but not Neu5Acα2-6LacNAc) from S.
pneumoniae (recombinant in E. coli; Glyko/ProZyme, San
Leandro, CA, USA), broad-range sialidase (SA; 1.5 mU/
reaction, to digest Neu5Acα2-3Gal and Neu5Acα2-6Gal)
from Arthrobacter ureafaciens (recombinant in E. coli;
Calbiochem), α1,3/4-fucosidase (α3/4Fuc; 0.1 mU/reaction,
to digest Fucα1-3(Galβ1-4)GlcNAc but not Fucα1-2Galβ1-
3GlcNAc) from Xanthomonas sp. (Calbiochem), α1,2-
fucosidase (α2Fuc; 0,15 mU/reaction to digest Fucα1-2Gal
but not Fucα1-3GlcNAc or Fucα1-4GlcNAc) from Xantho-
monas manihotis (Glyko/ProZyme), α-mannosidase (αMan;
50 mU/reaction, to digest the high-mannose type N-glycans)
from Jack beans (Canavalia ensiformis; Sigma-Aldrich),
endo-β-galactosidase (2.5 mU/reaction, to digest poly-
lactosamines) from Escherichia freundii (Seikagaku Corp.,
Tokyo, Japan) and β-N-acetylglucosaminidase (βGN;
9.4 mU/reaction, to digest GlcNAcβ1-3LacNAc but not
GalNAcβ1-4GlcNAc) from S. pneumoniae (recombinant in
E. coli, Calbiochem). Reactions with approximately 1–
10 pmol of oligosaccharides were carried out by overnight
digestion at +37°C in 10 μL of 50 mM sodium acetate
buffer pH 5.5.Digested glycan fractions were purified for
analysis by solid-phase extraction with graphitized carbon as
described above.
Mass spectrometry
Matrix-assisted laser desorption-ionization time-of-light
(MALDI-TOF) MS was performed with a Bruker Ultraflex
TOF/TOF instrument (Bruker Daltonics Inc, Bremen,
Germany). Neutral glycans were detected in positive ion
reflector mode as [M+Na]+ ions and acidic glycans were
detected in negative ion reflector mode as [M-H]-ions.
Relative intensities of identified glycan signals were
calculated separately for neutral and acidic glycan profiles.
Signal intensities were determined using Flexanalysis 3.0
software (Bruker Daltonics). The present glycan profiles
were extracted from the resulting signal lists by removing
the effect of isotopic pattern overlapping, multiple alkali
metal adduct signals, products of elimination of water from
the reducing oligosaccharides, contaminating signals from
endoglycoceramidase enzyme preparation and other inter-
fering mass spectrometric signals not arising from the
glycan components in the sample. The resulting glycan
signal intensities in overall profiles were summarized to be
100% in order to allow comparison between samples as
described [28, 33].
For mass spectrometric fragmentation analysis, glycans
were permethylated by a solid-phase microcolumn technique
[34]. Mass spectrometric fragmentation of permethylated
glycans was performed using the Bruker Ultraflex TOF/
TOF instrument according to manufacturer’s instructions.
High resolution and mass accuracy analyses were achieved
by matrix-assisted laser desorption/ionization Fourier trans-
form ion cyclotron mass spectrometry (MALDI-FT-ICR-MS;
9.4 T ApexUltra equipped with a combisource; Bruker
Daltonics) using 2,5-dihydroxybenzoic acid (20 mg/mL in
30% acetonitrile) as a matrix. A set of 4 assigned sialylated
N-glycans were used for internal calibration.
Nuclear magnetic resonance spectroscopy
The isolated glycans were purified for 1H NMR spectros-
copy by gel filtration chromatography [28]. Prior to NMR
experiments the saccharides were dissolved in D2O and
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evaporated to dryness. The samples were then dissolved in
280 μL of D2O (99.996 atom %; Cambridge Isotope
Laboratories) in Shigemi NMR tubes (Shigemi Co., LTD).
The experiments were carried out on a Varian Unity
INOVA 600 MHz spectrometer equipped with a cryoprobe
for enhanced sensitivity. All spectra were measured at
23°C. In recording one-dimensional 1H spectra presatura-
tion was used for water suppression.
Immunocytochemistry and lectin staining
FITC-labeled lectin and anti-carbohydrate Ab binding was
used to study the cell surface carbohydrate expression.
Cells grown on 8-well chamber slides were fixed with 4%
paraformaldehyde at RT for 10–15 min and washed with
PBS. FITC-labeled lectin in dilution of 5–40 μg/mL in 1%
human serum albumin (HSA)-PBS (Finnish Red Cross
Blood Service, Finland) was incubated at RT for 60 min.
For Ab stainings non-specific binding sites were blocked
with 3% HSA-PBS for 30 min at RT. Primary Abs were
diluted in 1% HSA-PBS (1:10–1:200) and incubated for
60 min at room temperature (RT), followed by washings 3
times with PBS. Secondary Abs were diluted in 1% HSA-
PBS and incubated for 60 min at RT in the dark. Staining
with secondary Ab alone was carried out as a control for
each experiment. Cells were washed 3 times with PBS and
mounted in Vectashield mounting medium containing
DAPI-stain (Vector Laboratories, UK). Stainings were
observed with Zeiss Axioskop 2 plus-fluorescence micro-
scope (Carl Zeiss Vision GmbH, Germany) with FITC and
DAPI filters. Images were taken with Zeiss AxioCam MRc-
camera and with AxioVision Software 3.1/4.0 (Carl Zeiss).
Flow cytometry
Cells were washed with PBS and harvested into single cell
suspensions by 0.25% trypsin/1 mM EDTA solution
(Gibco). Detached cells were centrifuged at 300×g for
5 min at RT. Cell pellet was washed twice with 1% BSA-
PBS (ultrapure BSA, Sigma), centrifuged at 600×g and
resuspended in 1% BSA-PBS. Cells were placed in conical
tubes in aliquots of 70,000 to 83,000 cells each. Cell
aliquots were incubated with one of the FITC-labeled lectin
for 20 min at room temperature. Lectins were used in
dilution of 5 μg/105 cells in 1% BSA-PBS. Primary Abs
were incubated (4 μL/100 μL cell suspension/50,000 cells)
for 30 min at RT and washed once with 0.3% BSA-PBS
before secondary antibody detection with Alexa Fluor 488
goat anti-mouse (1:500) for 30 min at RT in the dark. As a
negative control, cells were incubated without primary Ab
and otherwise treated similar to labeled cells. After
incubation cells were washed with 1% BSA-PBS, centri-
fuged and resuspended in 1% BSA-PBS. Binding was
detected by flow cytometry (FACSAria, Becton Dickinson)
and fluorescence was measured using 530/30 nm and 575/
25 nm bandpass filters. Data analysis was made with BD
FACSDiva™ Flow Cytometry Software Version 5.0.2.
Results
Profile of the mesenchymal stem cell glycome
To study the overall glycome of MSCs, bone marrow-
derived cells were either cultured in proliferative state or
differentiated into osteogenic direction. N-glycans were
released enzymatically from cell lysates by peptide: N-
glycosidase F (PNGase F) digestion, O-glycans chemically
by non-reductive β-elimination, and glycosphingolipid
glycans enzymatically by endoglycoceramidase digestion.
Mass spectrometric profiling of purified MSC N-glycans
(Fig. 1a,b) showed 253 different signals, of which 50 major
neutral and 50 major acidic signals are listed in Table 1 as
well as visualized in Fig. 1c–f. Known polyhexose
contaminations [28], marked with asterisks, were discarded
from the derived diagrams. The O-glycan profile of bone
marrow-derived MSCs revealed 42 different signals. Of
these, 10 major acidic signals are listed in Table 1, and the
most abundant neutral signal is visualized in Fig. 3. In the
lipid glycan profile, 63 signals were observed and 15 major
acidic and 20 major neutral signals are listed in Table 1.
Using a mass matching approach, monosaccharide
compositions could be proposed for the different glycan
signals (Table 1) and annotated in stem cell glycome
profiles (Fig. 1e,f). The relative intensities for all the
detected glycan signals have been calculated. The relative
intensity of a single peak is expressed as percentages of
total glycan profile, which has been given a value of 100%.
We and others have documented that the percentages
determined in this way are useful for relative quantitative
comparison of glycan profile changes [28, 33]. The mean
values of 5 different biological replicates are shown. The
glycan profiles were highly similar in the 5 different MSC
lines analyzed, as can be determined from the small
deviations within the observed glycan profiles (Fig. 1c,d).
The small profile differences between the 5 biological
replicates, also observed for the lineage-committed cells,
indicates that MSCs have a very characteristic N-glycome
and that the glycome change during osteogenic differenti-
ation occurs in a predetermined fashion.
N-glycans were grouped according to composition
calculation into different glycan classes, e.g. mannose-
type, complex-type and hybrid-type structures (Fig. 1e,f).
Mannose-type N-glycans dominated in the neutral N-glycan
profile comprising 78% of MSC signals and 58% of osteo-
blast signals. Complex-type N-glycans comprised 12% of
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MSC signals and 25% of osteoblast signals, while only 9% of
MSC signals and 16% of osteoblast signals were determined
as hybrid-type. In the acidic N-glycan fraction, complex-type
N-glycans comprised the majority of the total glycan profile,
80% in MSCs and 86% in osteoblasts. Hybrid-type and
monoantennary N-glycans were less abundant. There were
few signals that could not be assigned to glycan structures by
mass matching approach.
Fig 1 Mass spectrometric N-glycome profile of MSCs. Mass spectra
of neutral (a) and acidic (b) N-glycans from bone marrow (BM)-
derived MCSs are shown. Fifty major glycan peaks from five studied
MSC lines (black bars) as well as their osteoblast counterparts (grey
bars) are derived from mass spectrometric data (lines from a to c and
b to d) and visualized according to their relative intensities (c neutral
N-glycans; d acidic N-glycans). In panel e, neutral N-glycans and in
panel f acidic N-glycans are grouped according to their structural
classes. Glycan species are annotated with proposed structures derived
by mass calculation. Blue square represents N-acetylglucosamine,
green circle mannose, yellow circle galactose, red triangle fucose,
pink diamond N-acetylneuraminic acid and P either sulfate or
phosphate. Known polyhexose contaminations are marked with
asterisks
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Table 1 Major mass spectrometric glycan signals of mesenchymal stem cells (MSC) and their osteogenic counterparts (OG)
Neutral N-glycans Acidic N-glycans Neutral lipid glycans












771.26 H2N2 1.1 1.0 1,200.42 S1H3N2 0.8 0.6 527.16 H3 22.3 9.1
917.32 H2N2F1 1.4 2.1 1,354.41 H4N3P1 0.1 0.6 568.19 H2N1 17.3 13.3
933.31 H3N2 2.1 2.1 1,362.47 S1H4N2 2.2 0.5 609.21 H1N2 0.0 1.1
1,031.33 unknown 0.3 0.6 1,403.49 S1H3N3 0.4 0.3 730.24 H3N1 22.5 25.2
1,079.38 H3N2F1 3.6 3.2 1,500.47 H4N3F1P1 0.3 0.7 755.27 H1N2F1 0.9 0.0
1,095.37 H4N2 2.3 2.3 1,557.48 H4N4P1 0.0 0.8 771.26 H2N2 15.4 24.8
1,136.40 H3N3 0.7 0.7 1,565.55 S1H4N3 2.7 1.4 892.29 H4N1 0.0 0.9
1,241.43 H4N2F1 0.4 0.6 1,678.60 S2H2N3F1 1.6 0.7 933.32 H3N2 9.0 12.8
1,257.42 H5N2 8.5 9.1 1,711.61 S1H4N3F1 2.5 2.3 974.34 H2N3 0.3 0.0
1,282.45 H3N3F1 0.6 0.8 1,719.54 H5N4P1 0.8 4.1 1,031.00 unknown 0.3 0.8
1,298.45 H4N3 1.3 1.9 1,727.60 S1H5N3 2.5 1.8 1,038.35 H4N1F1 0.0 0.4
1,339.48 H3N4 0.1 0.1 1,768.57 S1H4N4 1.3 0.5 1,079.38 H3N2F1 0.2 0.4
1,393.00 unknown 0.1 0.2 1,865.60 H5N4F1P1 0.3 2.6 1,095.37 H4N2 4.2 5.7
1,403.48 H5N2F1 0.4 0.5 1,873.66 S1H5N3F1 2.0 1.5 1,136.40 H3N3 2.2 2.2
1,419.48 H6N2 15.4 10.5 1,889.65 S1H6N3 2.7 2.5 1,241.43 H4N2F1 0.2 0.4
1,428.51 H3N3F2 0.0 0.0 1,914.68 S1H4N4F1 1.3 1.0 1,298.45 H4N3 1.2 1.1
1,444.51 H4N3F1 0.8 1.5 1,930.68 S1H5N4 11.2 11.0 1,339.48 H3N4 0.3 0.1
1,460.50 H5N3 1.5 2.8 2,002.70 S2H4N3F1 0.3 0.2 1,419.48 H6N2 0.7 0.4
1,485.53 H3N4F1 0.8 0.6 2,035.71 S1H6N3F1 0.4 0.4 1,460.50 H5N3 0.6 0.4
1,501.53 H4N4 0.3 0.9 2,076.74 S1H5N4F1 31.0 36.4 1,501.53 H4N4 0.4 0.0
1,565.53 H6N2F1 0.2 0.1 2,092.73 S1H6N4 0.8 1.3 1,743.58 H8N2 0.2 0.1
1,581.53 H7N2 12.1 8.7 2,156.74 S1H5N4F1P1 0.0 0.6 1,784.61 H7N3 0.2 0.2
1,590.57 H4N3F2 0.1 0.3 2,174.79 S1H4N6 0.0 0.1 1,882.68 H4N3F4 0.1 0.2
1,606.56 H5N3F1 1.2 1.9 2,178.61 S2H5N3P2 0.0 0.1 Acidic Lipid Glycans
1,622.56 H6N3 2.4 4.5 2,188.76 G1H6N4P1 0.0 0.2 632.20 S1H2 32.1 26.1
1,647.59 H4N4F1 0.3 0.6 2,221.78 S2H5N4 4.4 4.0 923.30 S2H2 17.3 10.2
1,663.58 H5N4 5.0 8.1 2,222.80 S1H5N4F2 1.8 1.7 997.34 S1H3N1 11.4 25.3
1,688.61 H3N5F1 0.4 0.3 2,230.73 H6N5F1P1 0.1 0.9 1,126.38 S2H2N1 0.0 2.2
1,743.58 H8N2 15.3 9.4 2,279.82 S1H5N5F1 0.7 0.4 1,184.42 S1H2N2F1 3.9 6.5
1,752.62 H5N3F2 0.0 0.2 2,295.81 S1H6N5 2.3 1.8 1,200.42 S1H3N2 4.9 0.0
1,768.61 H6N3F1 0.4 0.8 2,367.83 S2H5N4F1 5.0 3.4 1,216.41 G1H3N2 1.1 0.0
1,784.61 H7N3 0.2 0.3 2,368.85 S1H5N4F3 1.0 1.4 1,362.47 S1H3 8.4 13.6
1,793.64 H4N4F2 0.2 0.2 2,383.83 S2H6N4 0.0 0.2 1,403.49 S1H3N3 2.8 2.1
1,809.64 H5N4F1 2.4 7.5 2,390.77 S2H5N3F2P1 0.5 0.0 1,565.55 S1H4N3 4.4 0.0
1,825.63 H6N4 0.1 0.3 2,406.76 S2H6N3F1P1 0.6 0.3 1,606.56 S1H3N4 1.5 0.0
1,905.63 H9N2 13.8 8.0 2,441.87 S1H6N5F1 8.1 5.3 1,727.60 S1H5N3 1.4 2.0
1,955.70 H5N4F2 0.4 1.1 2,586.91 S2H6N5 0.7 0.8 1,768.63 S1H4N4 2.0 0.0
1,971.69 H6N4F1 0.1 0.3 2,587.93 S1H6N5F2 0.5 0.4 1,889.65 S1H6N3 1.7 0.0
1,987.69 H7N4 0.0 0.1 2,660.94 S1H7N6 0.4 0.4 2,019.72 S1H5N3F2 3.7 3.7
1,996.72 H4N5F2 0.1 0.1 2,732.97 S2H6N5F1 1.8 1.3 Acidic O-glycans
2,012.72 H5N5F1 0.1 0.1 2,733.99 S1H6N5F3 1.0 0.4 827.22 H2N2P1 32.4 24.8
2,028.71 H6N5 0.8 1.7 2,807.00 S1H7N6F1 3.0 1.3 964.33 S2H1N1 4.0 9.5
2,041.00 unknown 0.2 0.2 2,878.00 S3H6N5 0.5 1.8 973.28 H2N2F1P1 1.6 2.0
2,067.69 H10N2 1.1 0.8 2,879.02 S2H6N5F2 0.2 0.6 1,038.36 S1H2N2 19.3 39.7
2,101.76 H5N4F3 0.3 0.3 2,880.04 S1H6N5F4 0.2 0.0 1,118.32 S1H2N2P1 2.2 5.6
2,174.77 H6N5F1 0.7 2.2 3,024.06 S3H6N5F1 0.3 0.2 1,329.46 S2H2N2 9.4 16.7
2,229.74 H11N2 0.1 0.1 3,098.10 S2H7N6F1 0.5 0.4 1,403.49 S1H3N3 2.0 0.0
2,320.83 H6N5F2 0.0 0.1 3,171.14 S2H6N5F4 0.1 0.4 1,475.44 S2H2N2F1 6.6 0.3
2,393.85 H7N6 0.1 0.2 3,172.13 S1H8N7F1 0.6 0.0 1,637.45 S2H3N2F1 4.8 1.20
2,539.90 H7N6F1 0.0 0.1 3,390.21 S2H7N6F3 0.4 0.2 1,678.51 S2H2N3F1 3.2 0.0
Proposed compositions are calculated on basis of mass matching approach and annotated as follows: H hexose, N N-acetylhexosamine, F
deoxyhexose, S N-acetylneuraminic acid, G N-glycolylneuraminic acid, P sulfate or phosphate
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The N-glycan profiles of bone marrow-derived MSCs
and their osteogenic counterparts showed clear characteris-
tic differences (Fig. 1). While high-mannose structures were
more dominant in stem cells, complex-type N-glycans
lacking N-acetylneuraminic acids (S) and neutral hybrid-
type N-glycans were enriched in cells differentiated into
osteogenic direction. High-mannose type N-glycans con-
taining more than 6 hexoses (H) were enriched in MSCs. In
differentiated cells, smaller mannose-type N-glycans were
relatively more abundant (Fig. 1e). In the acidic N-glycan
fraction (Fig. 1f), a characteristic feature of the differenti-
ated cells was the abundance of sulfate or phosphate ester
modifications (P) in both complex-type and hybrid-type
N-glycans. In stem cells, the acidic N-glycan profile
contained relatively more glycans with 2 or more deoxy-
hexose (F) residues and larger N-glycans with 5 or more
N-acetylhexosamine (N) residues. Trace amounts of struc-
tures containing N-glycolylneuraminic acid (G) were also
detected, including the acidic glycosphingolipid glycan
signal G1H3N2 (Table 1). These can be considered
markers of cells cultured in the presence of animal-derived
materials, as reported both for embryonic stem cells [35]
and MSCs [30]. N-glycan signals including G1H5N4 that
have been reported earlier [30] were detected, but they were
not among the listed 50 most abundant acidic N-glycan
signals. The observed xenoantigen contamination is most
likely originated from animal-derived components in the
cell culture media used.
The mass spectrometric profile of MSC N-glycans was
supported by 1H NMR profile of the same structures.
Neutral and acidic N-glycan pools were again analyzed
separately and the observed spectra were analyzed based on
reference data [36–38]. As expected, the detected structures
were among the most abundant glycan signals observed by
the MS approach. The major signals in the neutral N-glycan
pool corresponded to high-mannose type N-glycan struc-
tures and they could be annotated as glycans with
compositions H7N2, H8N2, and H9N2. In the sialylated
N-glycan pool biantennary complex-type N-glycans with
type 2 N-acetyllactosamine (LacNAc) antennae were
detected. Some of the antennae appeared to be non-
sialylated and a some of the detected signals were con-
sistent with core α1-6-linked fucose. Both α2-6- and
α2-3-linked sialic acids were detected, and quantitation of
the corresponding signals showed that the predominant
linkage was α2-3. The observed signals could be annotated
as glycans with compositions S1H5N4, S1H5N4F1,
S2H5N4, and S2H5N4F1.
In O-glycan mass spectrometric profiling, both Core-1
sized, with proposed H1N1 core composition, and larger
acidic O-glycans, mainly H2N2 as core composition, were
detected (Table 1). A striking feature in both cell types was
the abundance of O-glycans containing sulfate or phosphate
ester modifications. Significantly less neutral O-glycans
were detected and the recovered neutral O-glycan fraction
was contaminated by residual N-glycans. Therefore, only 1
neutral O-glycan could be reliably analyzed with the proposed
composition of H2N2 (Fig. 3). The major difference between
the O-glycan profiles of stem cells and lineage-committed
cells was observed in fucosylated acidic structures, which
were markedly enriched in MSCs (Table 1).
In glycosphingolipid profiling, isolated glycans were
observed in both neutral and acidic fractions (Table 1). The
proposed compositions indicated the presence of ganglio-
series (e.g. S2H2 structure), globo-series (e.g. H4N1
structure), and lacto/neolacto-series glycosphingolipids
(e.g. S1H4N2 structure) in both MSCs and differentiated
cells. One of the main differences detected between the
MSCs and the differentiated cells was that the MCSs
expressed more small ganglio-type glycans S1H2 and
S2H2, whereas differentiation was accompanied by an
increased expression of larger glycans, such as S1H3N1.
The performed mass spectrometric profiling experiments
did not give direct information about the absolute quanti-
ties of analytes in the 6 separately analyzed glycan
fractions. However, further information about the relative
proportions of the fractions could be obtained in separate
experiments. The ratio between neutral and acidic N-
glycans was determined by treating acidic glycan fractions
with sialidase, thus converting them into neutral structures.
Digestion products were further analyzed together with
neutral N-glycans, and proportions of derived glycans were
determined. The molar amount of neutral N-glycans was
found to equal approximately twice the molar amount of
acidic N-glycans (data not shown). In order to estimate the
relative proportions of different glycan classes, only simple
conclusions can be drawn. We were repeatedly able to
recover and analyze significantly more N-glycans than
either lipid- or O-linked glycans from all the cell types
studied.
Verification of identified stem cell glycan structures
In addition to MS and NMR profiling, further structural
information was needed for the assignment of precise
glycan structures. Enzymatic digestions with specific
glycosidases were performed in order to verify either
specific bonds between monosaccharides or specific mono-
saccharide locations, of which fucose is shown as an
example in Fig. 2a. Here, α1,3/4-fucosidase digestion is
shown to remove 2 mass spectrometric signals from the
neutral N-glycan spectra of bone marrow derived MSCs.
These signals correspond to multiply fucosylated structures
and their disappearance from the MS spectra indicates
either Lea or Lex terminal structures in MSC N-glycans.
The same signals were not sensitive to α1,2-fucosidase
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digestion (data not shown). The neutral N-glycan fraction
was further analyzed by specific galactosidase enzymes.
Many diantennary-size N-glycans were digested by β1,4-
galactosidase, whereas β1,3-galactosidase did not digest
any of the glycans in question. Therefore, we suggest that it
is more likely that the fucosylated antennae contain Lex
than Lea (data not shown).
Major findings with exoglycosidase digestions are
presented in Fig. 3 for the major glycan signals in each
separate glycan fraction. N-glycan signals proposed as
mannose-type N-glycans were shown by α-mannosidase
digestion to have non-reducing terminal α-mannose resi-
dues consistent with the initial assignment. Also the
proposed hybrid-type signals were shown to be sensitive
to α-mannosidase treatment. All detected sialic acid
residues in O-glycans were α2-3-linked; whereas in N-
glycans also α2-6-linkage was observed, as indicated by
the resistance of certain sialylated glycans to S. pneumoniae




glycans and high resolution MS.
α3/4-fucosidase digestion is
shown (a) to remove annotated
glycan signals of MSC
N-glycans. MS/MS fragmenta-
tion is shown to verify a glyco-
sphingolipid glycan structure
(b). MALDI-FTICR MS analy-
sis provides evidence for 5
sulfated, but not phosphated
glycan species (c). Glycan
annotations are as in Fig. 1
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sialidase. The only detected neutral O-glycan core was
capped with β1-4-linked galactose. Glycosphingolipid
glycans were not characterized with glycosidase digestions
in the present study.
Neutral N- and O-glycan samples of bone marrow-
derived MSCs were further subjected to enzymatic endo-β-
galactosidase treatment and analyzed by MALDI-TOF
mass spectrometry. In both neutral N- and O-glycan spectra
Fig 3 Structure assignments of the most abundant mass spectrometric
glycan signals detected in MSCs. N-glycan (left panel), O-glycan
(upper right panel) and glycosphingolipid glycan structures (lower
right panel) are shown to be determined by glycosidase digestions
and/or MS/MS fragmentation of permethylated glycans. Structures
detected in NMR analyses are marked with asterisks. Glycosidase
abbreviations are as in the section Materials and Methods. Glycosidase
treatment with no effect on the structure is assigned as n.e. Glycan
annotations are as in Fig. 1 with the addition of grey circle/square as
unspecified hexose/N-acetylhexosamine, respectively
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a signal at m/z 568 corresponding to H2N1 [M+Na]+ ion
appeared after endo-β-galactosidase treatment (data not
shown). This represents a characteristic cleavage product of
endo-β-galactosidase. Endo-β-galactosidase is specific for
linear poly-LacNAc substrates and the detected fragment
indicates a non-reducing terminal structure Gal-GlcNAcβ1-
3Galβ1-4GlcNAc- (the released H2N1 fragment under-
lined). The high relative intensity of the cleavage product
indicates that it is derived from the breakdown of several
poly-LacNAc containing glycans in both N- and O-glycans.
For further verification of glycan structures of bone
marrow-derived MSC glycan fractions were permethylated
for MS/MS fragmentation analyses. The detected fragment
ions indicative of specific glycan structures are shown in
Fig. 3. The fragmentation of a disialylated GD3-type
glycosphingolipid glycan is shown as an example in
Fig. 2b. Mass spectrometric fragmentation was shown to
support the findings of glycome profiling and proposed
compositions based on mass matching (Fig. 3). Core fucose
was confirmed as the main fucosylation in N-glycans,
although fucosylated antennae were also detected. The
fragmentation patterns of glycosphingolipid glycans were
consistent with the common ganglioside structures GM3,
GD3 (Fig. 2b) and GD1, globoside Gb4, and lacto/
neolacto-series poly-LacNAc. All major glycosphingolipid
classes were therefore indicated to be expressed in MSCs
(Fig. 3). MS/MS fragmentation patterns were also indica-
tive of the presence of linear poly-LacNAc chains in MSC
glycans. Candidate glycans carrying poly-LacNAc include
the acidic N-glycan S1H6N5F1 and the acidic glycosphingo-
lipid glycan S1H4N2. The fragmentation pattern of the third
most abundant acidic N-glycan S1H6N5F1 was consistent
with a biantennary N-glycan structure in which one antenna
had S1H1N1 composition (putative sialylated LacNAc)
and the other H2N2 composition (putative linear poly-
LacNAc). Especially the presence of a fragmentation
product at m/z 2,141.7 (calc. m/z 2,142.1) corresponding to
S1H4N3F1 [M+Na]+ ion supported the assignment. This
fragment lacked the putative poly-LacNAc antenna and
contained a single free hydroxyl group indicating only one
branch point (Fig. 3). The detected fragments from the
acidic glycosphingolipid glycan S1H4N2 indicated that the
mass spectrometric signal comprised at least 2 structures, of
which the structure A was consistent with a linear structure
with alternating hexose and N-acetylhexosamine residues
(Fig. 3), corresponding to putative linear poly-LacNAc.
Taken together, the data indicated presence of linear poly-
LacNAc in N- and O-glycans, and possibly also in
glycosphingolipids of bone marrow-derived MSCs.
Several glycan peaks with 80 Da mass addition were
observed in acidic mass spectrometric glycome profiles of
MSCs and especially in the osteogenic cells derived from
them (Table 1). To discriminate between putative sulfate or
phosphate groups, the profiles were further analyzed using
MALDI-FTICR-MS in negative-ion mode (Fig. 2c). Here,
the masses of sialylated N-glycans could be registered with
an average mass deviation of 1.1 ppm. Five glycan species
with potential sulfation or phosphorylation, which were
registered in the same spectrum, were concluded to be
sulfated glycans with average mass deviation of 0.6 ppm.
Phosphorylation could be ruled out on the basis of the large
mass deviation (between 5.6 and 6.5 ppm) between
calculated and registered masses (Fig. 2c inset). Unfortu-
nately, acidic O-glycans could not be analyzed in this way,
due to the limited amounts of O-glycans available for
analyses.
Cell surface glycome analysis by glycan binding proteins
Since the MS and NMR profiling of MSC glycome
encompassed the overall cellular glycome, including intra-
cellular glycans, further verification of cell surface presen-
tation of the observed glycan structures was needed.
Cytochemical stainings of MSCs and osteoblasts derived
thereof were performed using numerous different glycan
binding proteins, either lectins or Abs. In Fig. 4 staining of
MSCs by sialic acid binding lectins from Maackia
amurensis (MAA) and Sambucus nigra (SNA) is shown
as an example. The strong staining with MAA (Fig. 4a)
indicates α2,3-sialic acid expression on the surface of
Fig 4 Sialic acid expression on
MSCs determinated by lectin
binding. Maackia amurensis
(MAA) binding to α2-3-sialic
acid is shown throughout the
cell culture (a), whereas
Sambucus nigra (SNA) binding
to α2-6-sialic acid is relatively
weak (b)
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MSCs, in comparison with the relatively weak staining with
SNA (Fig. 4b). Both NMR profiling and α2-3-linkage
specific sialidase digestion supported the finding that α2-3-
linked sialic acids were abundant in MSCs (Fig. 3).
Many glycan binding proteins showed differential
binding to MSCs as compared to osteoblasts. In Fig. 5 Ab
against sLex epitope is shown to stain almost exclusively in
MSCs (Fig. 5a) when compared to their differentiated
counterparts (Fig. 5b). This is in good agreement with our
findings of the mass spectrometric analyses that were
performed after glycosidase treatments. Fucosidase analy-
ses indicated that neutral N-glycans carry either α1-3- or
α1-4-linked fucose residues, and galactoses in both neutral
N- and O-glycans were shown to be mainly β1-4-linked as
demonstrated by susceptibility to β1,4-galactosidase and
resistance to β1,3-galactosidase (Fig. 2a). Also, specific
sialidase treatment (Fig. 3) and lectin staining (Fig. 4)
showed that α2-3-linked sialic acids are abundant in MSCs.
The increased fucosylation of sialylated O-glycans (Table 1)
could also contribute to enriched sLex epitopes, as the
O-glycans were shown using specific sialidase digestions
to be α2-3-sialylated (Fig. 3). However, only minor
fucosylated glycosphingolipid glycans in MSCs were
detected. Therefore, the multifucosylated sialylated N-
glycans together with the fucosylated and sialylated O-
glycan are likely candidates for the carriers of sLex in
MSCs.
The Solanum tuberosum lectin (STA), recognizing
mainly linear poly-LacNAc chains, i.e. the blood group i,
was shown to pronouncedly stain MSCs (Fig. 5c), whereas
staining in their osteogenic derivates was hardly visible
(Fig. 5d). In contrast, the cytochemical staining with
Phytolacca americana lectin (PWA), recognizing mainly
branched poly-LacNAc chains, i.e. blood group antigen I,
showed no discrimination between the 2 cell types (data not
shown). This is consistent with the presence of very large
acidic N-glycans in MSC profile (for example S1H8N7F1
in Fig. 1f) as well as with the mass spectrometric
fragmentation analyses demonstrating linear poly-LacNAc
type chains in both major acidic N-glycans and glyco-
sphingolipid glycans of MSC (Fig. 3). Also endo-β-
galactosidase digestion liberated H2N1 terminal fragments
from neutral N-glycans directly indicating the presence of
linear poly-LacNAc chains in MSCs. These structural
analyses revealed potential STA lectin ligand structures in
both N-glycans and glycosphingolipid glycans of MSCs.
Cytochemical lectin stainings of cell surface mannose
structures, which were observed in MS and NMR profiling,
were also performed. Hippeastrum hybrid (HHA) lectin
gave clear staining result of bone marrow-derived MSCs to
support the cell surface localization of mannosylated
structures (data not shown).
Flow cytometric analyses were performed to further
deepen the knowledge of MSC surface glycan structures.
Fig 5 Cytochemical staining of
MSCs and their osteogenic
counterparts by glycan binding
proteins. Anti-sLex Ab stains
MSCs (a), while the staining is
hardly visible in cells differenti-
ated into osteogenic direction
(b). Solanum tuberosum (STA)
lectin recognizes epitopes on
stem cell surfaces (c), whereas
their osteogenic counterparts are
hardly recognized (d)
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63 different commercially available Abs against glycan
epitopes were tested. As an example of this data, Fig. 6
shows increased surface expression of epitopes SSEA-4
(Fig. 6a) and sLex (Fig. 6c) in bone-derived MSCs when
compared to their osteogenic counterparts (Fig. 6b,d). In
contrast, anti-Lex Ab did not stain the cells (Fig. 6e,f),
which was typical of the majority of the Abs screened in the
study. Although the staining results showed clear SSEA-4
epitope expression in stem cells (Fig. 6a), no corresponding
signal, with S1H4N1 composition, could be detected in
mass spectra of acidic glycosphingolipids. Instead, very
low intensity signal of SSEA-3 composition (H4N1) was
seen in neutral glycosphingolipid profile of differentiated
osteoblasts. Interestingly, hardly any staining with SSEA-3
Ab was detected in any of the cells analyzed (data not
shown). Flow cytometric analysis of sLex epitope expres-
sion (Fig. 6c) was not as demonstrative as immunostaining
result described above (Fig. 5a). Here, approximately 70%
of MSCs (Fig. 6c) and still more than 35% of osteoblasts
(Fig. 6d) were shown to be sLex positive. The contradictory
results are likely due to methodological differences in the 2
staining procedures.
Discussion
Stem cell glycosylation has been shown to have charac-
teristic features in numerous reports relying on lectin and
glycan-antibody stainings mainly in embryonic stem cells
[25–27, 39]. In this study we have widened the research on
human stem cell glycosylation into MSCs, which hold an
enormous therapeutic potential, especially in regenerative
medicine. We combined mass spectrometric and NMR
spectroscopic glycan profiling, verified by enzymatic
glycosidase digestions and mass spectrometric fragmenta-
tion, with analysis with glycan binding proteins, using both
fluorescence microscopy and flow cytometry. This unique
combination of methods verifies that certain glycan
structures provide a signature which allows discrimination
between MSCs and their osteogenic counterparts. Here,
Fig 6 Flow cytometry histo-
grams of glycan antibody
binding in MSCs and their
osteogenic counterparts. Anti-
SSEA-4 (a, b), anti-sLex (c, d)
and anti-Lex (e, f) Ab stainings
are visualized in MSCs
(a, c, e) and in differentiated
osteoblasts (b, d, f). Histogram
plots with the overlay images of
staining antibodies are shown
with red fill in comparison to
histogram plot of unstained cells
(grey fill)
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some of the glycan epitopes found to be characteristic of
MSCs and their differentiation are discussed.
Our data imply that a relatively high amount of high
mannose glycans in the total glycan pool might be a
common feature of stem cell glycomes, including human
MSCs as shown in the present study, embryonic stem cells
(unpublished data) and hematopoietic stem cells [28]. It
should be realized that the total glycomes include also
intracellular glycans, and these typically contain more high-
mannose glycans than e.g. individual secreted proteins or
glycans from plasma membranes. The major ER and Golgi
type glycans in the glycan profile might reflect the
metabolic status of cells. However, in the case of cultured
cells, such as the MSCs in the present study, cell culture
conditions may have a substantial effect on glycomes. It
would be a major challenge to increase the sensitivity of the
assay to enable the analysis of stem cells isolated directly
from tissues. So far this has been achieved only for
hematopoietic stem cells, which were also shown to contain
relatively high amounts of high-mannose glycans [28]. The
glycomes of the stem cells cultured under standard
conditions are useful for the characterization of cells aimed
for therapy, even when the glycomes may not correspond to
the natural glycosylation of the cells.
We were able to observe increased expression of linear
poly-N-acetyllactosamine (poly-LacNAc) chains in MSCs
as compared with osteoblasts by mass spectrometric
fragmentation analysis, endo-β-galactosidase digestion,
and Solanum tuberosum lectin (STA) staining. Poly-
LacNAcs have been shown to undergo structural changes
during human development, wherein linear chains in fetal
blood cells (i-antigen) are changed to branched chains (I-
antigen) in the adult [40]. However, early embryonic cells
express large branched poly-LacNAc (embryoglycan),
whereas the i-antigen appears in postimplantation embryos
[21]. The SSEA-1 Lex structure, which is commonly used
as a marker for mouse embryonic stem cells, is expressed
within embryoglycan, and even though human embryonic
cells do not express SSEA-1, they contain embryoglycan
consisting of poly-LacNAc, that is considered to be an
evolutionary conserved glycan backbone [21]. In general,
poly-LacNAcs are thought to act as scaffolds presenting
glycan epitopes to lectins in a multivalent fashion. For
example, the galectins, a family of β-galactoside binding
lectins involved in a wide range of adhesion and signaling
phenomena [41], have higher affinity for poly-LacNAcs
than for single LacNAc units [42–44]. Galectins are
hypothesized to modulate their biological functions accord-
ing to fine specificities for target glycans [44]. MSCs
express galectins [45], and the immunomodulatory effects
of galectins have been shown to reduce GvHD in a mouse
model [46]. In addition, exposure to galectin-1 induces
skeletal muscle differentiation of human fetal MSCs [47].
The expression of SSEA-4, but not SSEA-3, on bone
marrow-derived MSCs was demonstrated in this study by
antibody staining analyzed by flow cytometry. However,
very low levels of either of the corresponding glycosphingo-
lipid glycan signals were observed in mass spectrometric
profiles. The glycosphingolipid markers SSEA-3 and SSEA-
4 are considered to be markers of human embryonic stem
cells [27, 39, 48]. However, they do not seem to be essential
for pluripotency [49]. Our results confirm the previously
reported expression of SSEA-4 also on bone marrow MSCs
[50–53]. Interestingly, one of the studies reported SSEA-4
expression to markedly increase under serum free culturing
conditions [51]. In contrast to the lack of SSEA-3
expression reported here, evidence of SSEA-3 expression
in MSCs does exist [50, 52]. However, absence of both
SSEA-3 and SSEA-4 on adult bone marrow MSCs has also
been reported [54]. The contradictory results are likely due
to either cell line-specific expression of these epitopes or
differences in culture conditions.
We observed the presence of multiple ganglioseries
glycosphingolipids on both MSCs and their differentiated
variants. We detected changes in glycosphingolipid com-
position during the differentiation of MSCs, such as a
tendency of smaller GM3/GD3 structures to change into
larger gangliosides, including GD1. Several ganglioseries
glycosphingolipids are expressed on human embryonic
stem cells, and differentiation has been reported to induce
a change in their ganglioside profile [39]. Especially,
increased expression of disialylgangliosides, including
GD3 and GD2, after embryonic stem cell differentiation,
has been reported [39]. GD2 has previously been reported
to be a potential marker of bone marrow-derived MSCs
[55], but our results do not support this finding, since we
did not observe GD2 (composition S2H2N1) at all in
MSCs, but rather in osteoblasts derived from them. Human
periodontal bone marrow MSCs have been reported to
express GM1 [56], which was found also in the present
study by MS/MS fragmentation, whereas after neuronal
differentiation both GM1 and GT1b were detected [56]. In
contrast to the present study, no other gangliosides, like
GM3/GD3, could be detected [56]. The differences may be
caused by methodological differences between the two
studies or different bone marrow sources used in them.
Sulfated carbohydrate epitopes, which we observed to be
markedly enriched both in the N-glycan and O-glycan
profiles of osteogenically differentiated MSCs, are involved
in a variety of biological recognition events. Some
galectins, especially galectins 1–3, have been shown to
bind 3′-sulfated LacNAcs better than their unsulfated
counterparts [44]. Sulfation affects also the binding of
certain siglecs, a family of sialic acid binding lectins
involved in the regulation of the immune system [57], to
their ligands. L-selectin ligand glycoproteins, which are
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involved in leukocyte-endothelium interactions, are known
to carry sulfated sLex structures [58]. Keratan sulfate
epitopes Tra-1–60 and Tra-1–81 have been reported as
markers of embryonic stem cells [27, 39]. These sulfated
poly-LacNAc structures (sulfated forms of the i-antigen) are
closely related to the structures observed enriched in
differentiated osteoblasts in the present study. The produc-
tion of sulfated glycosaminoglycans, such as keratan
sulfate, is considered a hallmark of MSC differentiation
commitment into osteogenic lineage and it co-occurs with
increased expression of glycosaminoglycan biosynthetic
enzymes [59]. It is also noteworthy that the bone
sialoprotein, an osteoblast-associated marker, which is
expressed exclusively in bone and particularly during early
stages of bone formation [60], has been reported by
metabolic labeling to contain sulfated N- and O-glycans in
rats [61]. However, sulfated glycans have not been
observed in human bone sialoprotein [62].
In the present study, sialyl-Lewis x (sLex) is introduced
as a novel characteristic glycan epitope expressed on
human MSCs derived from bone marrow and to some
extent also on osteogenically differentiated cells derived
from them. sLex is best known as a selectin ligand, and for
its involvement in leukocyte homing as well as in cancer
metastasis [63, 64]. In addition, sLex has been reported to
mediate fucosylation-dependent homing of both hemato-
poietic [65, 66] and mesenchymal [67] stem cells into bone
marrow. MSCs have also been shown to roll on endothelial
cells in a P-selectin-dependent manner [68]. Interestingly, a
major selectin ligand PSGL-1 carries sLex on O-glycans
[69], whereas selectin ligands carried on N-glycans have
also been reported [70], especially in hematopoietic and
mesenchymal stem cells [67, 71]. In the present study we
identified both N- and O-glycans as potential carriers of
sLex epitope in MSCs.
We report here that α2-3-linked sialic acid, which is also
terminal residue of the sLex epitope, is a typical structure
on the surface of MSCs, Although these sialic acids are
common terminal glycan structures, the ratio of α2-3- and
α2-6-sialylation may affect intercellular interactions or
differentiation of cells by modulating the binding of glycan
receptors, such as siglec 2 (CD22) [72, 73] or selectin–sLex
adhesion. α2-3-sialylation has also been shown to regulate
T-cell biology through inhibiting galectin-1 binding [74].
Interestingly, terminal α2-3-sialic acid on a N-glycan has
been shown to inhibit binding of CD44 to hyaluronic acid
[75]. As MSCs express α2-3-sialylated glycoform of CD44
[67], α2-3-sialylation may regulate MSC adhesion to the
extracellular matrix. We have previously shown α2-3-
sialylation to be increased also on cord blood CD133+
hematopoietic stem cells as compared to differentiated
CD133− cells [28]. In the present study, MSC O-glycans
were shown to contain sialic acid exclusively in α2-3
linkage, indicating differential regulation of sialylation
between the different glycan classes.
In conclusion, we analyzed the glycome of bone
marrow-derived MSCs using MS and NMR profiling,
further structure verification and a broad range of glycan
binding proteins. Comparison of the obtained data to the
profiles of osteogenically differentiated cells clearly indi-
cated cell type specific variation in the glycosylation
patterns. Certain glycan structures seem to be indicative of
the “stemness” nature of cells. The conservation of a
specific glycan structure between different stem cell types
within the same species, or conservation between different
species on a certain stem cell type, may be an indication of
an essential function for the glycan structure in multipotent
cells [19]. At least to our knowledge, no glycosylation
studies on MSCs from different species have been
conducted, but we have demonstrated here similarities in
stem cell glycosylation between human MSCs and both
human embryonic stem cells [22–24] and hematopoietic
stem cells [28]. It seems evident that glycan structures may
be”switched on” and “off” on cell surfaces several times
during cellular differentiation in developmental processes,
as implied by the transition between linear and branched
poly-LacNAc structures [21]. Here, similar transition in
multiple glycan structures was demonstrated during MSC
differentiation into osteogenic direction. The more precise
biological functions of these glycosylation characteristics
remain to be defined in the future.
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